It can be hypothesized that AGCT patients harboring characteristics of a more aggressive tumor, such as a TP53 mutation, might respond better to chemotherapy than patients without this variant since chemotherapy targets rapidly dividing cells. This evidence concerns the gene TP53 and neoplasm.